Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Panacea Biotec is currently trading at Rs. 114.70, up by 8.70 points or 8.21% from its previous closing of Rs. 106.00 on the BSE.
The scrip opened at Rs. 104.10 and has touched a high and low of Rs. 118.00 and Rs. 103.90 respectively. So far 29,087 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 149.75 on 17-Sep-2012 and a 52 week low of Rs. 63.50 on 04-Jun-2012.
Last one week high and low of the scrip stood at Rs. 118.00 and Rs. 103.90 respectively. The current market cap of the company is Rs. 702 crore.
The promoters holding in the company stood at 74.81% while Institutions and Non-Institutions held 2.91% and 22.28% respectively.
Panacea Biotec, India’s highly progressive research based health management company has entered into a strategic alliance with Kremers Urban Inc. (part of UCB Group) for 11 high barriers to entry generics, whose market size in US at the innovator level is around $4 billion.
The first product in this portfolio to reach the market is Tacrolimus Capsules that is being launched in US in Nov 2012. The company was granted approval of the product from United States Food and Drug Administration (US FDA) in September 2012.
Tacrolimus Capsules is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received organ transplants.
Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |